Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequences

• Published in: World journal of urology 2022-12, Vol.40 (12), p.2947-2954
• Main Authors: Haack, Maximilian, Miksch, Vanessa, Tian, Zhe, Duwe, Gregor, Thomas, Anita, Borkowetz, Angelika, Stroh, Kristina, Thomas, Christian, Haferkamp, Axel, Höfner, Thomas, Boehm, Katharina
• Format: Article
• Language: English
• Subjects: Biopsy; Humans; Image-Guided Biopsy - methods; Magnetic resonance imaging; Magnetic Resonance Imaging - methods; Male; Medicine; Medicine & Public Health; Multiparametric Magnetic Resonance Imaging; Multivariate analysis; Nephrology; Oncology; Original; Original Article; Prostate - pathology; Prostate cancer; Prostate-Specific Antigen - analysis; Prostatic Neoplasms - diagnostic imaging; Prostatic Neoplasms - pathology; Retrospective Studies; Urology
• ISSN: 1433-8726; 0724-4983; 1433-8726
• DOI: 10.1007/s00345-022-04197-8

Purpose EAU guidelines recommend multiparametric MRI of the prostate (mpMRI) prior to biopsy to increase accuracy and reduce biopsies. Whether biopsy can be avoided in case of negative mpMRI remains unclear. Aim of this study is to evaluate predictors of overall prostate cancer (PCa) in negative mpMRI. Methods A total of 216 patients from 2018 to 2020 with suspicion of PCa and negative mpMRI (PI-RADS ≤ 2) were interviewed by telephone about outcome and further follow-up. Clinically significant PCa (csPCa) was defined as ISUP ≥ 2. Patients with vs. without biopsy and with vs. without PCa were compared. Univariate and multivariate analyses were performed to evaluate predictors of PCa occurrence in patients with negative mpMRI. Results 15.7% and 5.1% of patients with PI-RADS ≤ 2 on mpMRI showed PCa and csPCa, respectively. PCa patients had higher PSAD (0.14 vs. 0.09 ng/ml 2 ; p  = 0.001) and lower prostate volume (50.5 vs. 74.0 ml; p  = 0.003). Patients without biopsy (25%) after MRI were older (69 vs. 65.5 years; p  = 0.027), showed lower PSA (5.7 vs. 6.73 ng/ml; p  = 0.033) and lower PSA density (0.09 vs. 0.1 ng/ml 2 ; p  = 0.027). Multivariate analysis revealed age (OR 1.09 [1.02–1.16]; p  = 0.011), prostate volume (OR 0.982 [0.065; 0.997]; p  = 0.027), total PSA level (OR 1.22 [1.01–1.47], p  = 0.033), free PSA (OR 0.431 [0.177; 0.927]; p  = 0.049) and no PI-RADS lesion vs PI-RADS 1–2 lesion (OR 0.38 [0.15–0.91], p  = 0.032.) as predictive factors for the endpoint presence of PCa. Conclusions Biopsy for selected patient groups (higher age, prostate volume and free PSA as well as lower PSA-Density) with negative mpMRI can be avoided, if sufficient follow-up care is guaranteed. Detailed counseling regarding residual risk for undetected prostate cancer should be mandatory.